Published in Clin Cancer Res on November 01, 2008
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Main roads to melanoma. J Transl Med (2009) 1.67
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov (2015) 1.65
Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol (2012) 1.64
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
Primary anorectal melanoma: an update. J Cancer (2012) 1.55
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Sinonasal tumors: a clinicopathologic update of selected tumors. Eur Arch Otorhinolaryngol (2012) 1.43
Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol (2013) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res (2009) 1.38
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol (2011) 1.26
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer (2010) 1.24
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
A melanoma molecular disease model. PLoS One (2011) 1.15
Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int J Clin Oncol (2010) 1.14
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol (2010) 1.06
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs (2011) 1.00
Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (2014) 1.00
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA. World J Gastroenterol (2009) 0.98
Genetics and genomics of melanoma. Expert Rev Dermatol (2009) 0.98
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer (2013) 0.96
Conjunctival melanoma: a review of conceptual and treatment advances. Clin Ophthalmol (2013) 0.94
Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol (2014) 0.92
Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res (2012) 0.91
NUAK2: an emerging acral melanoma oncogene. Oncotarget (2011) 0.90
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer (2013) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88
Molecular markers of tumor progression in melanoma. Curr Genomics (2009) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am (2009) 0.87
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget (2015) 0.87
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel. PLoS One (2014) 0.85
Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) (2013) 0.85
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med (2010) 0.84
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Primary mucosal melanoma of the sinonasal tract: a clinicopathologic and immunohistochemical study of thirty-two cases. Head Neck Pathol (2014) 0.82
Molecular bases of cutaneous and uveal melanomas. Patholog Res Int (2011) 0.81
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol (2014) 0.81
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther (2014) 0.81
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget (2016) 0.81
Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol (2014) 0.80
The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol (2014) 0.80
Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. J Biol Chem (2013) 0.79
Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population. Head Neck Pathol (2012) 0.79
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity. PLoS Comput Biol (2014) 0.79
Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye (Lond) (2012) 0.79
Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One (2014) 0.78
SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget (2016) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Therapeutic opportunities in noncutaneous melanoma. Ther Adv Med Oncol (2009) 0.78
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging (2014) 0.78
DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. Biomed Res Int (2015) 0.77
Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol (2015) 0.77
Discrepant alterations in main candidate genes among multiple primary melanomas. J Transl Med (2014) 0.77
KIT in melanoma: many shades of gray. J Invest Dermatol (2015) 0.77
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Malignant melanoma of the nasal cavity: a case report with examination of KIT and platelet derived growth factor receptor-α(PDGFRA). Rare Tumors (2011) 0.76
Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget (2015) 0.76
Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA. Rare Tumors (2012) 0.76
A malignant transformation in a pre-existing benign scrotal naevus. J Clin Diagn Res (2012) 0.75
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol (2013) 0.75
Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. Oncotarget (2017) 0.75
Oral malignant melanoma: A report of two cases with BRAF molecular analysis. Oncol Lett (2014) 0.75
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther (2016) 0.75
Targeted therapy for cancer: the gastrointestinal stromal tumor model. Surg Oncol Clin N Am (2013) 0.75
Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses. Clin Med Insights Case Rep (2017) 0.75
Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol Cell Pharmacol (2015) 0.75
Is UV an etiological factor of acral melanoma? J Expo Sci Environ Epidemiol (2015) 0.75
Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75
Malignant melanoma in Chile: different site distribution between private and state patients. Biol Res (2014) 0.75
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist (2015) 0.75
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol (2004) 4.46
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol (2002) 4.09
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Gastrointestinal stromal tumour. Lancet (2007) 3.25
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Gastrointestinal stromal tumour. Lancet (2013) 3.19
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 3.00
Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol (2002) 2.95
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol (2002) 2.85
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
Determination of stromal signatures in breast carcinoma. PLoS Biol (2005) 2.84
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol (2011) 2.72
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol (2008) 2.68
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev (2006) 2.46
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol (2008) 2.38
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J (2009) 2.31
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol (2002) 2.22
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19
Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol (2005) 2.19
The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci U S A (2006) 2.17
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A (2006) 2.08
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 1.98
Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg (2003) 1.95
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol (2008) 1.95
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (2009) 1.94
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94